


Form PTO-1595 (Rev. 07/05)
OMB No. 0651-0027 (exp. 6/30/2008)

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies) PROCYON BIOPHARMA INC. Additional name(s) of conveying party(ies) attached? ☐ Yes ☐ No	2. Name and address of receiving party(ies) Name: AMBRILIA BIOPHARMA INC. Internal Address: _____ Street Address: 1000 chemin du Golf _____ City: Verdun State: Quebec Country: CANADA Zip: H3E 1H4 Additional name(s) & address(es) attached? ☐ Yes ☒ No
3. Nature of conveyance/Execution Date(s): Execution Date(s) 03/01/2006 ☐ Assignment ☐ Merger ☐ Security Agreement ☒ Change of Name ☐ Joint Research Agreement ☐ Government Interest Assignment ☐ Executive Order 9424, Confirmatory License ☐ Other _____	4. Application or patent number(s): ☐ This document is being filed together with a new application. A. Patent Application No.(s) 10/291,360; 10/429,668; 10/902,935; 10/857,358 B. Patent No.(s) 6,107,103; 5,428,011; 6,362,165; 6,528,655; 6,455,587; 6,506,786; 6,608,100; 6,610,689; 6,656,965; 6,677,367; 6,528,532; 6,638,921; 6,632,816 Additional numbers attached? ☐ Yes ☐ No
5. Name and address to whom correspondence concerning document should be mailed: Name: Ronald S. Kosie Internal Address: _____ Street Address: 1100 René-Lévesque Blvd. West 25th Floor City: Montréal State: Québec, CANADA Zip: H3B 5C9 Phone Number: (514) 397-6942 Fax Number: (514) 397-8515 Email Address: rsk@bcf.ca	6. Total number of applications and patents involved: 17 7. Total fee (37 CFR 1.21(h) & 3.41) \$ 680.00 ☐ Authorized to be charged by credit card ☒ Authorized to be charged to deposit account ☐ Enclosed ☐ None required (government interest not affecting title) 8. Payment Information a. Credit Card Last 4 Numbers _____ Expiration Date _____ b. Deposit Account Number 02-3980 Authorized User Name _____
9. Signature:  _____ Signature Date July 20, 2006 Ronald S. Kosie Registration No. 28,814 Total number of pages including cover sheet, attachments, and documents: 6 Name of Person Signing	

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

CH \$680.00 023980 10291360

700276755

PATENT
REEL: 017971 FRAME: 0053

**PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RE : REGISTRATION OF DOCUMENT
APPLICANT/OWNER : PROCYON BIOPHARMA INC.
ATTORNEY DOCKET NO : 10329-027 RSK/JFO/ao

Montréal, Québec, Canada
July 20, 2006

MAIL STOP ASSIGNMENT RECORDATION SERVICES
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

SIR:

Enclosed herewith for recordation against the patents and patent applications listed below a document entitled "Certificate of Amendment" duly executed by the President of Ambrilia Biopharma Inc. (formerly Procyon Biopharma Inc.) and approved by the director of Industry Canada.

US patent application no.: 10/291,360 filed on November 8, 2002
US patent application no.: 10/429,668 filed on May 1, 2003
US patent application no.: 10/902,935 filed on August 2, 2004
US patent application no.: 10/857,358 filed on June 1st, 2004
US patent application no.: 08/949,993 filed on October 14, 1997 now **United States Patent no. 6,107,103**
US patent application no.: 07/899,535 filed on June 16, 1992 now **United States Patent no. 5,428,011**
US patent application no.: 09/534,615 filed on March 27, 2000 now **United States Patent no. 6,362,165**
US patent application no.: 09/963,329 filed on September 26, 2001 now **United States Patent No.: 6,528,655**
US patent application no.: 09/526,209 filed on March 15, 2001 now **United States Patent no.: 6,455,587**
US patent application no.: 09/781,219 filed on February 13, 2001 now **United States Patent no.: 6,506,786**
US patent application no.: 10/244,622 filed on September 17, 2002 now **United States Patent no.: 6,608,100**
US patent application no.: 10/244,644 filed on September 17, 2002 now **United States Patent no.: 6,610,689**
US patent application no.: 10/244,383 filed September 17, 2002 now **United States Patent no.: 6,656,965**
US patent application no.: 10/244,672 filed on September 17, 2002 now **United States Patent no.: 6,677,367**
US patent application no.: 10/143,095 filed on May 13, 2002 now **United States Patent no.: 6,528,532**
US patent application no.: 10/183,468 filed on June 28, 2002 now **United States Patent no.: 6,638,921**
US patent application no.: 10/326,488 filed on December 23, 2002 now **United States Patent no.: 6,632,816**

The United States Patent Office is hereby authorized to charge the amount of \$ 680.00 to our **Deposit Account no. 02-3980** as recordation fee of the enclosed document against the above-identified United States patents and patent applications.

Also, please charge any fee deficiency or credit any overpayment to said deposit account.

**PATENT
REEL: 017971 FRAME: 0054**



Industry Canada

Industrie Canada

**Certificate
of Amendment****Canada Business
Corporations Act****Certificat
de modification****Loi canadienne sur
les sociétés par actions****AMBRILIA BIOPHARMA INC.****388112-1**

Name of corporation-Dénomination de la société

Corporation number-Numéro de la société

I hereby certify that the articles of the
above-named corporation were amended:Je certifie que les statuts de la société
susmentionnée ont été modifiés:

- a) under section 13 of the *Canada Business Corporations Act* in accordance with the attached notice;
- b) under section 27 of the *Canada Business Corporations Act* as set out in the attached articles of amendment designating a series of shares;
- c) under section 179 of the *Canada Business Corporations Act* as set out in the attached articles of amendment;
- d) under section 191 of the *Canada Business Corporations Act* as set out in the attached articles of reorganization;

- ☐ a) en vertu de l'article 13 de la *Loi canadienne sur les sociétés par actions*, conformément à l'avis ci-joint;
- ☐ b) en vertu de l'article 27 de la *Loi canadienne sur les sociétés par actions*, tel qu'il est indiqué dans les clauses modificatrices ci-jointes désignant une série d'actions;
- ☒ c) en vertu de l'article 179 de la *Loi canadienne sur les sociétés par actions*, tel qu'il est indiqué dans les clauses modificatrices ci-jointes;
- ☐ d) en vertu de l'article 191 de la *Loi canadienne sur les sociétés par actions*, tel qu'il est indiqué dans les clauses de réorganisation ci-jointes;

Richard G. Shaw
Director - Directeur

March 1, 2006 / le 1 mars 2006

Date of Amendment - Date de modification

Canada



Industry Canada Industrie Canada
Canada Business Loi canadienne sur les
Corporations Act sociétés par actions

FORM 4
ARTICLES OF AMENDMENT
(SECTIONS 27 OR 177)

FORMULAIRE 4
CLAUSES MODIFICATRICES
(ARTICLES 27 OU 177)

1 - Name of the Corporation - Dénomination sociale de la société
PROCYON BIOPHARMA INC.

2 - Corporation No. - N° de la société
3881121

3 - The articles of the above-named corporation are amended as follows: Les statuts de la société mentionnée ci-dessus sont modifiés de la façon suivante :

Section 1 of the Articles of Continuance is replaced by the following:

" Name of Corporation: AMBRILIA BIOPHARMA INC."

Signature 	Printed Name - Nom en lettres moulées HANS J. MADER	4 - Capacity of - En qualité de President	5 - Tel. No. - N° de tél. (514) 822-3232
FOR DEPARTMENTAL USE ONLY - À L'USAGE DU MINISTÈRE SEULEMENT			
		BATCH 2006-03-01 9:00	

IC 3069 (2003/05)

Canada